Trial reportHepatology communications2026
Effect of tiomolibdate choline on copper balance in patients with Wilson disease: An open-label phase 2 trial.
Trial report in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWilson disease (WD) is a rare disorder of copper (Cu) disposition. Tiomolibdate choline (TMC, bis-choline tetrathiomolybdate, ALXN1840), an oral Cu-binding agent, was investigated for the treatment of WD. The effect of repeat-dose TMC on Cu balance, serum Cu parameters, and safety was evaluated in an open-label, single-arm phase 2 study in 9 patients with WD.
methodsEnrolled patients with WD were admitted to a clinical research unit (CRU) and initiated on a Cu-controlled diet. Copper intake (food and drink) and output (feces and urine) were collected during a baseline period (days -4 through -1) and after initiation of daily TMC (days 1-8 and 25-39). Patients were allowed to leave the CRU during an interim period (days 9-24) but continued outpatient TMC treatment. Patients started on 15 mg/day TMC on day 1 with planned dose escalation to 30 mg/day TMC on day 29.
resultsTMC showed a statistically significant reduction in daily Cu balance from baseline over the entire study period (days 1-39), attributed to increased fecal Cu excretion. The decrease in Cu balance was rapid, with a statistically significant decrease beginning on day 4. The cumulative mean decrease from baseline in Cu balance was -6.08 mg over 21 days. Plasma total Cu and directly measured non-ceruloplasmin-bound Cu levels increased immediately, consistent with Cu mobilization into blood and formation of stable tripartite complexes of Cu, TMC, and albumin. TMC was well tolerated. Alanine aminotransferase elevations that occurred were mild and reversible with dose modulation.
conclusionTMC's reduction in Cu balance in WD patients, along with strong mobilization of Cu, supports the therapeutic potential of TMC in WD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.